Clinical Trial

Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration

Study acronym: BURGUNDY
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injections and via the port delivery (PD) implant in participants with neovascular age-related macular degeneration (nAMD).
Protocol Amendment History 3 changes
notable Primary completion pushed: 2026-03-10 -> 2026-08-25 2026-08-15
notable Primary completion moved earlier: 2026-08-01 -> 2026-03-10 2026-08-14
notable Trial sites reduced: 48 -> 39 locations 2026-05-07
Trial Details
NCT Number NCT04567303
Lead Sponsor Hoffmann-La Roche
Conditions Macular Degeneration
Enrollment 177 participants
Start Date 2020-10-28
Primary Completion 2026-08-25 (estimated)
Study Completion 2026-08-25 (estimated)
Updated on ClinicalTrials.gov 2026-08-14